Top Markets
Coin of the day
InDex Pharmaceuticals Holding AB (publ) InDex Pharmaceuticals Holding AB (publ)

InDex Pharmaceuticals Holding AB (publ)

INDEX
Rangering i aksjer #28996
InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to... InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to developing therapeutic solutions for patients affected by ulcerative colitis. The company's flagship drug candidate, Cobitolimod, is presently in Phase III clinical trials, targeting the treatment of moderate to severe ulcerative colitis. Furthermore, InDex is progressing a pipeline of other DNA-based immunomodulatory sequences, which are in the preclinical phase, designed to address various immunological conditions. This enterprise was established in 2000 and operates from its headquarters in Solna, Sweden.
Aksjekurs
$0.04406501
Sist synkronisert: 2024-07-09
Markedsverdi
$23.47M
Endring (1 dag)
-0.48%
Endring (1 år)
0.00%
Land
SE
Handel InDex Pharmaceuticals Holding AB (publ) (INDEX)

Kategori

P/S-forhold for InDex Pharmaceuticals Holding AB (publ) (INDEX)
P/S-forhold per 2026 TTM: 0
Ifølge InDex Pharmaceuticals Holding AB (publ) sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for InDex Pharmaceuticals Holding AB (publ) fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH